Core Insights - Volta Labs and Ginkgo Bioworks have announced the integration of the Callisto™ Sample Prep System into Ginkgo's routine Illumina sequencing workflow, enhancing operational efficiency in genomics applications [1][3]. Company Overview - Volta Labs specializes in genomics applications and has developed a digital fluidics platform aimed at maximizing performance and scalability in sample preparation, providing high consistency in biological research [4]. - Ginkgo Bioworks operates as a leading platform for cell programming, offering end-to-end services across various markets, including food, agriculture, pharmaceuticals, and biosecurity [5]. Technological Advancements - The Callisto system is designed to automate complex processes such as PacBio library preparation and double-sided size selection for Illumina sequencing, addressing challenges in traditional liquid handling technologies [2][3]. - The newly released Double-Sided Size Selection app allows labs using Illumina, Element Biosciences, and Ultima Genomics platforms to purify and select optimal fragment sizes for sequencing, showcasing Callisto's advanced capabilities in liquid separation and DNA elution [3]. Strategic Partnership - Ginkgo Bioworks has been a key partner for Volta Labs, contributing to the refinement of solutions for high-throughput labs, indicating a strong collaborative relationship that may lead to further applications in the future [3].

Core Insights - Ginkgo Bioworks has announced a collaboration with the European Health and Digital Executive Agency (HaDEA) to develop rapid metagenomic next-generation sequencing (mNGS) solutions for identifying respiratory pathogens, with funding of up to €24 million over four years [1][2][6] Group 1: Project Overview - The project, named RApid Next Generation Sequencing for Effective Medical Response (RANGER), aims to create a point-of-care mNGS solution that allows for rapid diagnostics of respiratory viruses, potentially transforming the diagnostic landscape [2][3] - The device is designed to provide a turnaround time of 6 hours, enabling hospitals to triage patients more effectively and reduce the burden of prolonged isolation and costly inpatient stays [3][6] Group 2: Technological Capabilities - The RANGER device will utilize "agnostic diagnostics," allowing it to sequence and identify virtually any respiratory pathogen, which enhances pandemic preparedness [4][6] - The program includes the option for the European Commission to procure 200 devices at preferred pricing, facilitating widespread deployment across EU/EEA healthcare systems [4] Group 3: Implementation Phases - The project will be executed in three phases, starting with the integration of existing technologies into a benchtop device, followed by clinical trials in EU hospitals, and concluding with securing EU certification for the device [5][6] Group 4: Strategic Alignment - This collaboration aligns with HERA's mission to strengthen Europe's capacity to respond to health emergencies by enhancing diagnostic capabilities and reducing delays in pathogen identification [6][7] - The initiative is expected to improve hospital triage, infection control, and provide early-warning tools against emerging pathogens, reinforcing the EU's health resilience [6][8]

Core Viewpoint - Acurx Pharmaceuticals has received a new patent in Japan for DNA Polymerase IIIC Inhibitors, which is crucial for the development of its antibiotic candidate ibezapolstat for treating C. difficile Infection (CDI) [1][2] Company Developments - Acurx has expanded its patent portfolio with three U.S. patents, one Israeli patent, and now a Japanese patent, all related to its ACX-375C program [1] - The company is preparing for Phase 3 clinical trials for ibezapolstat, having received positive regulatory guidance from the EMA [2][3] - The Phase 3 trials will involve approximately 450 subjects, randomized in a 1:1 ratio to receive either ibezapolstat or standard care vancomycin [3] Clinical Trial Insights - The Phase 2 clinical trial demonstrated a 96% Clinical Cure rate for ibezapolstat, with 100% cure in the Phase 2a segment [6][7] - The Phase 2b trial showed that ibezapolstat was well-tolerated, with no serious adverse events reported [7] - Ibezapolstat treatment led to favorable changes in bile acid metabolism, which may reduce the likelihood of CDI recurrence [8][12] Market Context - CDI is a significant healthcare issue, with estimates of 500,000 infections annually in the U.S. and a mortality rate of approximately 9.3% [11] - The CDC has classified C. difficile as an urgent threat, highlighting the need for new antibiotics [10] Product Overview - Ibezapolstat is a novel, orally administered antibiotic targeting Gram-positive bacteria, specifically designed to maintain a healthy gut microbiome while treating CDI [9][13] - The drug has received QIDP designation and Fast Track status from the FDA, which may expedite its development process [10]

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. is set to host a presentation and Q&A session to review its business performance for Q4 and the full year of 2024 on February 25, 2025 [1] Group 1: Presentation Details - The presentation will begin at 5:30 p.m. ET and will be available on Ginkgo's investor relations website, with a replay option provided [2] - Questions can be submitted in advance via social media or email [2] Group 2: Company Overview - Ginkgo Bioworks is recognized as a leading platform for cell programming, offering comprehensive services across various sectors including food, agriculture, pharmaceuticals, and industrial chemicals [3] - The company is also focused on biosecurity, developing infrastructure and technologies to address biological threats [3]

Core Viewpoint - Ginkgo Bioworks Holdings, Inc. (DNA) experienced a significant stock price increase of 14.5% to $16.36, driven by positive investor sentiment regarding its proprietary cell programming platforms and strong revenue growth expectations [1][2]. Company Summary - Ginkgo Bioworks utilizes its Foundry and Codebase platforms to offer R&D services under collaboration and license agreements, along with biomonitoring and bioinformatic support services to public health authorities [2]. - The company is projected to report a quarterly loss of $1.45 per share, reflecting a year-over-year increase of 59.7%, while revenues are expected to reach $45.08 million, marking a 29.7% increase from the previous year [3]. - The consensus EPS estimate for Ginkgo Bioworks has remained stable over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Industry Context - Ginkgo Bioworks is part of the Zacks Medical - Biomedical and Genetics industry, which includes other companies like Krystal Biotech, Inc. (KRYS), that has shown a modest stock performance with a 0.7% increase [4]. - Krystal Biotech's EPS estimate has increased by 10.6% over the past month, indicating a significant year-over-year change of 330%, but it currently holds a Zacks Rank of 4 (Sell) [5].

Core Insights - Ginkgo Bioworks is launching the 2025 Ferment Series, an evolution of its annual conference aimed at advancing its mission of making biology easier to engineer [1][2] - The series will focus on specific areas within Ginkgo's cell engineering and biosecurity offerings, showcasing transformative solutions across various markets [2][3] Event Details - The Ferment Series will take place at Ginkgo's event venue in Boston's Seaport District, with a series of focused events throughout 2025 [1] - Each event will feature Ginkgo experts, partners, and industry leaders discussing applications of engineered biology [2] Technology and Innovations - Attendees will have the opportunity to see Ginkgo's technologies and innovations, including high-throughput AI-driven data generation services and automation systems [3] - New products and services will be highlighted, such as Ginkgo Datapoints and Ginkgo Biosecurity's monitoring and threat intelligence solutions [3] CEO Statement - Jason Kelly, CEO of Ginkgo Bioworks, emphasized the company's strengthened mission and the importance of showcasing their evolving platform and new capabilities at the 2025 Ferment events [4] 2025 Ferment Series Calendar - The series will include events focused on: - Summer: Datapoints x AI, focusing on data generation services and AI models for biotech R&D [5] - September: Ginkgo Biopharma Solutions, aimed at accelerating drug discovery and development [5] - October: Biosecurity, discussing strategies for biological risk management [5] - November: Automation, featuring demonstrations of Ginkgo's automation systems [6] Industry Engagement - Ginkgo will also participate in other industry conferences, such as World AgriTech and ABIM, to connect with partners and showcase its R&D capabilities [7][8]

Ginkgo Bioworks Holdings, Inc. (DNA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The ...

Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRCBOSTON, Jan. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and deploy a flexible, anaerobic-enabled laboratory automation system for the Great Lakes Bioenergy Research Center (GLBRC), a U.S. Department of Energy-funded Bio ...

Core View - Ginkgo Bioworks collaborates with Universal Cells, an Astellas company, to optimize next-generation iPSC-derived cancer cell therapies, leveraging Ginkgo's high-throughput biological approaches to address challenges in solid tumor therapy development [1] - The collaboration aims to enhance the potency and persistence of iPSC-derived immune cell therapeutics by combining Universal Cells' proprietary technologies with Ginkgo's expertise in CAR library design, screening, and immune cell engineering [2] Collaboration Details - The partnership focuses on improving the scalability and manufacturability of 'off-the-shelf' iPSC-derived cell therapies, which have the potential to transform cancer care [2] - Ginkgo's platform capabilities include CAR discovery and optimization, cell survival enhancement strategies, and gene editing tools for immune cell engineering, enabling rapid exploration and refinement of therapeutic designs [3] Ginkgo's Platform Strengths - Ginkgo employs computational tools, deep expertise in library assembly, and rigorous statistical analysis to accelerate the discovery and engineering of optimal therapeutic designs [3] - The company's high-throughput pooled and arrayed screening methods allow simultaneous testing of numerous CAR designs, aiming to improve immune cell persistence and functionality [3] Strategic Impact - The collaboration represents a significant milestone for Ginkgo as it expands its cell therapy portfolio and brings its immune cell engineering capabilities to a global pharmaceutical leader [4] - The partnership aims to optimize iPSC-derived allogeneic cell therapies, potentially improving patient outcomes and reshaping the treatment of solid tumors [4] Industry Context - Ginkgo Bioworks is a leading horizontal platform for cell programming, offering end-to-end services across diverse markets, including pharmaceuticals, food, agriculture, and industrial chemicals [5] - The company is also building next-generation biosecurity infrastructure and technologies to address global biological threats [5]

Company Presentation - Ginkgo Bioworks CEO Jason Kelly is scheduled to present at the 43rd Annual J P Morgan Healthcare Conference on January 16 2025 at 10 30 a m PT (1 30 p m ET) [1] - Further details webcast link and a replay of the presentation will be posted on the company's investor relations website [1] Company Overview - Ginkgo Bioworks is the leading horizontal platform for cell programming providing flexible end-to-end services across diverse markets including food and agriculture pharmaceuticals and industrial and specialty chemicals [2] - Ginkgo Biosecurity is building next-generation infrastructure and technologies to help global leaders predict detect and respond to biological threats [2] Contact Information - Investor contact email is provided for inquiries [3] - Media contact email is provided for inquiries [3]